Phase 1 study to evaluate the safety of dasatinib in relapsed and refractory angioimmunoblastic T-cell lymphoma

Phase 1 study to evaluate the safety of dasatinib in relapsed and refractory angioimmunoblastic T-cell lymphoma - Dasatinib safety in AITL

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025856

Enrollment

Registered

2017-01-30

Start date

2017-05-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

angioimmunoblastic T-cell lymphoma

Interventions

dasatinib

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Pathologic diagnosis of AITL is made (2)Relapse after chemotherapy or SD/PD in the most recent cherapy (3)Tumor biopsy sample is available

Exclusion criteria

Exclusion criteria: Treated with other anti-cancer drugs, calcineurin inhibitors, and steroid (excluding 10mg or less predonisolone)

Design outcomes

Primary

Measure	Time frame
Safety of dasatinib in AITL	—

Countries

Japan

Contacts

Public ContactMamiko Sakata

Univercity of Tsukuba,Faculty of Medicine Department of Hematology

sakatama-tky@umin.net029-853-3127

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026